Selvita agrees subsidiary merger plan. Selvita stock is valued at PLN 363.4 million

Published on 10/18/2026 at 13:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Selvita stock had a PLN 363.4 million market value on October 16, 2026. The merger plan covers two wholly owned units and requires no new shares.

Merger and financial dates

Selvita subsidiaries agreed a merger plan on September 30, 2026, without issuing new shares.
First-half 2026 revenue was PLN 158.10 million, versus PLN 183.76 million a year earlier.
Selvita is scheduled to report its next results on November 19, 2026.

Selvita, PLSLVCR00029, Illustration mit AI erstellt.

Selvita (ISIN PLSLVCR00029) had a PLN 363.4 million market value on October 16, 2026, after its wholly owned subsidiaries agreed a merger plan. Bankier.pl reported on October 1, 2026, that Selvita Services would absorb PozLab under a simplified procedure.

Merger stays within group

The transaction is organizational rather than an external acquisition. Selvita owns both subsidiaries, and the plan provides for no capital increase or new shares. The merger becomes effective after registration in Poland's National Court Register, while PozLab's business continues at its existing location.

The company describes itself as an integrated service provider for drug discovery and drug development. Its website says the group supports customers from early drug discovery through the clinical stage of development, a model that makes the internal consolidation relevant to the Drug Development segment.

What does the merger change?

The immediate financial effect is limited because both subsidiaries are already fully consolidated. The plan is intended to simplify the group structure, reduce the costs of operating two entities and unify marketing and sales under one brand, according to Bankier.pl.

The wider operating picture remains mixed. In the first half of 2026, revenue was PLN 158.10 million, down from PLN 183.76 million a year earlier, while EBITDA fell to PLN 23.90 million from PLN 30.90 million, according to BiznesRadar on September 18, 2026. The Drug Development segment was a counterpoint, with commercial revenue of PLN 55.30 million, up 16.00 percent year over year, and EBITDA of PLN 16.10 million, up 26.00 percent.

Three dates and figures

On September 18, 2026, Selvita reported first-half revenue of PLN 158.10 million and appointed Rafa? Chwast as chief executive. On September 30, 2026, the subsidiary boards signed the merger plan. On October 1, 2026, Selvita announced the plan and stated that it would not affect consolidated financial statements.

Next report is due November 19

Selvita's next report is expected on November 19, 2026, according to the published company calendar. That date gives investors the next scheduled checkpoint for revenue, profitability and order intake after the first-half decline. A separate risk is contracting: Parkiet reported that contracts signed from mid-May were down 30.00 percent year over year, although Drug Development contracting was 23.00 percent higher year over year.

Market value and listing

Selvita closed at PLN 19.80 on GPW on October 16, 2026 at 4:59 p.m. CEST. Its market capitalization was PLN 363.4 million on that date. The further course of trading is shown by the continuously updated real-time quote of Selvita stock.